Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Texas researchers identify new detection method for circulating tumor cells

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

New research highlights the benefit of shortened radiation course for patients with non-invasive breast cancer

New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.

14 Dec 2009

NCKUH and NHRI sponsor virology lab in Vietnam Children’s Hospital

A Virology Lab in Children’s Hospital No. 1 (CH1), Ho Chi Minh City, Vietnam, sponsored by National Cheng Kung University Hospital (NCKUH) and National Health Research Institutes (NHRI) in Taiwan was launched on November 11th, 2009.

11 Dec 2009

Event proceeds to benefit Virginia G. Piper Cancer Center at Scottsdale Healthcare

Scottsdale Healthcare Foundation announced today that Daniel Von Hoff, MD will be Honoree at its 34th annual Honor Ball. Dr. Von Hoff, an oncologist and chief scientific officer at Scottsdale Healthcare's Virginia G. Piper Cancer Center, is known worldwide for his groundbreaking cancer research.

10 Dec 2009

NIH awards Lentigen a SBIR grant for program to generate Hepatitis C Virus-Like Particles

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business innovation research (SBIR) grant for a program on "A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus". In this program, Lentigen will collaborate with Epixis SA (Paris, France).

9 Dec 2009

Utility of CEH-EUS uses sonographic contrast agent to diagnose pancreatic tumors

Endoscopic ultrasonography (EUS) is a highly sensitive diagnostic method for the detection of small pancreatic carcinomas. Recently, there have been some reports describing the utility of contrast-enhanced harmonic EUS (CEH-EUS) which uses sonographic contrast agent for differentiation of a pancreatic mass.

9 Dec 2009

Phase II clinical trial results of Doxorubicin Transdrug announced

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces positive survival data in its phase II clinical trial with doxorubicin Transdrug® in patients with advanced hepatocellular carcinoma (primary liver cancer).

9 Dec 2009

Three university academic groups sponsored for the MetaMiner project

GeneGo, Inc., the leading systems biology tools company, announced today that Millipore Corporation has sponsored academic groups from University of Queensland, Sheffield and USC to become members of the collaborative MetaMiner (Stem Cells) project run by GeneGo. MetaMiner is a partnership program for the reconstruction of stem cell pathways and their application in analysis of experimental data as well as knowledge mining.

8 Dec 2009

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in its Phase I/IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in combination with standard antiviral treatment and vaccination in HBeAg-negative chronic hepatitis B-infected (HBV) patients.

8 Dec 2009

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

Novo Nordisk A/S and ZymoGenetics, Inc. today announced an agreement where Novo Nordisk in-licenses a fully-human anti-IL21 monoclonal antibody (IL-21 mAb) developed by ZymoGenetics, as well as broad intellectual property rights covering IL-21 mAb and the development of other IL-21 antibodies.

From Novo Nordisk 8 Dec 2009

ImmunoGen reports encouraging clinical data of IMGN901

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed on multiple prior treatment regimens.

6 Dec 2009

FDA approves new technology tool for breast cancer screening

The FDA has approved new technology that now allows radiologists to detect breast cancer sooner and faster. The SonoCine Automated Whole-breast Ultrasound Method and is being offered by only one facility in Arizona - Arizona Breastnet, in Scottsdale.

6 Dec 2009

Pfizer to present study findings from its expanded breast cancer portfolio

Pfizer Oncology announced today that it will be presenting study findings evaluating several compounds including those from its newly expanded breast cancer portfolio following the recent acquisition of Wyeth, focusing on the needs of multiple breast cancer patient populations at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) being held December 9 – 13.

4 Dec 2009

Endo Pharmaceuticals receives FDA complete response letter for AVEED NDA

Endo Pharmaceuticals today announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for its extended-duration testosterone undecanoate injection, AVEED(TM), for men diagnosed with low testosterone.

3 Dec 2009

Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC

Celsion Corporation, a leading oncology drug development company, today provided an update on the progress of its pivotal ThermoDox® Phase III “HEAT” trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Following recent regulatory approvals in China, Malaysia, Thailand and the Philippines, the study is now enrolling patients in eleven countries, with the majority of clinical sites located in the Asia Pacific region where HCC is most prevalent.

3 Dec 2009

New study links cigarette smoking with colorectal cancer

New study results strengthen the evidence that people who smoke cigarettes over a long period of time have an increased risk for developing colorectal cancer, even after adjusting for other risk factors.

3 Dec 2009

Occult lesions identified with BSGI can be localized using multi-modality imaging for needle biopsy

Dr. Jocelyn Rapelyea, Associate Director of Breast Imaging and Intervention at George Washington University Medical Center in Washington, D.C., demonstrated how occult lesions identified with Breast-Specific Gamma Imaging (BSGI) can be localized utilizing multi-modality imaging for needle biopsy as well, as for pre-operative localization today at the annual meeting of the Radiological Society of North America (RSNA).

2 Dec 2009

Annual screening ultrasound may benefit women who are at elevated risk for breast cancer

Results of a large-scale clinical trial presented today at the annual meeting of the Radiological Society of North America (RSNA) provide the first strong evidence of the benefit of annual screening ultrasound for women with dense breasts who are at elevated risk for breast cancer. In addition, the study confirmed that MRI is highly sensitive in depicting early breast cancer.

2 Dec 2009

CRO to run CEL-SCI's upcoming Phase III clinical trial

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today that it has retained the services of an international Contract Research Organization (CRO) to run CEL-SCI's upcoming Phase III clinical trial in advanced primary head and neck cancer with the Company's lead product candidate, Multikine®.

1 Dec 2009

Carcinoma News and Research

Further Reading

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Texas researchers identify new detection method for circulating tumor cells

New research highlights the benefit of shortened radiation course for patients with non-invasive breast cancer

NCKUH and NHRI sponsor virology lab in Vietnam Children’s Hospital

Event proceeds to benefit Virginia G. Piper Cancer Center at Scottsdale Healthcare

NIH awards Lentigen a SBIR grant for program to generate Hepatitis C Virus-Like Particles

Utility of CEH-EUS uses sonographic contrast agent to diagnose pancreatic tumors

Phase II clinical trial results of Doxorubicin Transdrug announced

Three university academic groups sponsored for the MetaMiner project

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

ImmunoGen reports encouraging clinical data of IMGN901

FDA approves new technology tool for breast cancer screening

Pfizer to present study findings from its expanded breast cancer portfolio

Endo Pharmaceuticals receives FDA complete response letter for AVEED NDA

Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC

New study links cigarette smoking with colorectal cancer

Occult lesions identified with BSGI can be localized using multi-modality imaging for needle biopsy

Annual screening ultrasound may benefit women who are at elevated risk for breast cancer

CRO to run CEL-SCI's upcoming Phase III clinical trial

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News